Private Wealth Advisors Inc. raised its stake in shares of Gilead Sciences Inc. (NASDAQ:GILD) by 1.8% during the second quarter, Holdings Channel reports. The fund owned 14,218 shares of the biopharmaceutical company’s stock after buying an additional 257 shares during the period. Private Wealth Advisors Inc.’s holdings in Gilead Sciences were worth $1,186,000 as of its most recent filing with the SEC.

Other large investors have also bought and sold shares of the company. Temasek Holdings Private Ltd increased its position in shares of Gilead Sciences by 8.1% in the first quarter. Temasek Holdings Private Ltd now owns 13,830,516 shares of the biopharmaceutical company’s stock worth $1,270,471,000 after buying an additional 1,035,592 shares during the period. Norges Bank purchased a new position in shares of Gilead Sciences during the fourth quarter worth $1,308,213,000. Geode Capital Management LLC increased its position in shares of Gilead Sciences by 1.3% in the first quarter. Geode Capital Management LLC now owns 12,410,846 shares of the biopharmaceutical company’s stock worth $1,137,969,000 after buying an additional 161,505 shares during the period. Canada Pension Plan Investment Board increased its position in shares of Gilead Sciences by 15.6% in the first quarter. Canada Pension Plan Investment Board now owns 4,955,996 shares of the biopharmaceutical company’s stock worth $455,258,000 after buying an additional 669,800 shares during the period. Finally, Prudential Financial Inc. increased its position in Gilead Sciences by 12.0% in the first quarter. Prudential Financial Inc. now owns 3,816,408 shares of the biopharmaceutical company’s stock valued at $350,575,000 after buying an additional 410,120 shares during the period. 77.96% of the stock is currently owned by institutional investors.

Shares of Gilead Sciences Inc. (NASDAQ:GILD) traded down 0.05% during mid-day trading on Friday, hitting $78.80. 10,307,872 shares of the stock traded hands. The stock has a market cap of $103.99 billion, a P/E ratio of 6.92 and a beta of 1.06. Gilead Sciences Inc. has a 12-month low of $76.67 and a 12-month high of $113.31. The firm’s 50 day moving average price is $79.54 and its 200-day moving average price is $86.33.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings results on Monday, July 25th. The biopharmaceutical company reported $3.08 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.02 by $0.06. The firm had revenue of $7.78 billion for the quarter, compared to analysts’ expectations of $7.80 billion. Gilead Sciences had a net margin of 50.50% and a return on equity of 106.75%. The firm’s quarterly revenue was down 5.7% on a year-over-year basis. During the same period in the prior year, the company posted $3.15 earnings per share. Analysts predict that Gilead Sciences Inc. will post $11.77 earnings per share for the current year.

The business also recently declared a quarterly dividend, which will be paid on Thursday, September 29th. Investors of record on Friday, September 16th will be issued a $0.47 dividend. The ex-dividend date is Wednesday, September 14th. This represents a $1.88 annualized dividend and a yield of 2.39%. Gilead Sciences’s dividend payout ratio is presently 16.56%.

GILD has been the subject of several research analyst reports. Jefferies Group reduced their price target on shares of Gilead Sciences from $93.00 to $91.00 and set a “hold” rating for the company in a research report on Wednesday, August 31st. Piper Jaffray Cos. restated an “overweight” rating and set a $108.00 price target on shares of Gilead Sciences in a research report on Wednesday, August 31st. Vetr upgraded shares of Gilead Sciences from a “buy” rating to a “strong-buy” rating and set a $93.97 price target for the company in a research report on Tuesday, July 26th. S&P Equity Research restated a “strong-buy” rating on shares of Gilead Sciences in a research report on Wednesday, July 27th. Finally, Morgan Stanley set a $100.00 price target on shares of Gilead Sciences and gave the stock a “hold” rating in a research report on Tuesday, September 6th. Nine analysts have rated the stock with a hold rating, eighteen have issued a buy rating and two have issued a strong buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and an average price target of $105.41.

In other Gilead Sciences news, EVP Paul Rutherford Carter sold 2,000 shares of the stock in a transaction on Friday, July 1st. The shares were sold at an average price of $83.12, for a total transaction of $166,240.00. Following the sale, the executive vice president now directly owns 63,122 shares of the company’s stock, valued at $5,246,700.64. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Chairman John C. Martin sold 100,000 shares of the stock in a transaction on Friday, July 1st. The stock was sold at an average price of $84.73, for a total transaction of $8,473,000.00. Following the sale, the chairman now directly owns 4,119,727 shares in the company, valued at $349,064,468.71. The disclosure for this sale can be found here. 1.40% of the stock is currently owned by corporate insiders.

About Gilead Sciences

Gilead Sciences, Inc is a research-based biopharmaceutical company. The Company focuses on the discovery, development and commercialization of medicines in areas of unmet medical need. The Company’s principal areas of focus include human immunodeficiency virus (HIV), liver diseases, such as chronic hepatitis C virus infection and chronic hepatitis B virus infection, cardiovascular, hematology/oncology and inflammation/respiratory.

5 Day Chart for NASDAQ:GILD

Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences Inc. (NASDAQ:GILD).

Receive News & Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.